Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03785340 · ClinicalTrials.gov registry record · Phase 3
Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)
A Phase 3 study, sponsored by Ocugen.
- Completed
- Registry status
- Phase 3
- Development phase
- 252
- Enrollment target
NCT03785340 is a Phase 3 study that has completed, run by Ocugen. The registered enrollment target is 252 participants.
The verdict
NCT03785340, a Phase 3 study, has completed, sponsored by Ocugen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 252 participants
- Enrollment target
Study Summary
This study evaluates the use of Brimonidine tartrate nanoemulsion eye drop solution in the treatment of Dry Eye Disease (DED). Half of participants will receive Brimonidine and half will receive ophthalmic buffered saline (placebo).
Interventions
- DRUG Placebos
- DRUG Brimonidine Tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2018-12-03 |
| Est. Completion | 2019-02-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03785340
The ClinicalTrials.gov registry entry for NCT03785340 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocugen, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03785340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03785340 about?
NCT03785340 is a clinical study titled "Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)". This study evaluates the use of Brimonidine tartrate nanoemulsion eye drop solution in the treatment of Dry Eye Disease (DED). Half of participants will receive Brimonidine and half will receive ophthalmic buffered saline (placebo).
What is the current status of trial NCT03785340?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 252 participants. The study started on 2018-12-03. Estimated completion is 2019-02-25.
What interventions are being tested in trial NCT03785340?
The interventions under investigation include: Placebos (DRUG), Brimonidine Tartrate (DRUG).
Who is sponsoring clinical trial NCT03785340?
This trial is sponsored by Ocugen, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.